Submitted by mphilemon@resea... on Mon, 01/10/2011 - 11:35
Please click each issue for edition topic links.
ASH Highlights: MDS 2011 — The Future Ain't What It Used to Be
ASH Highlights: Mantle-Cell Blues
ASH Shocker: Brentuximab Vedotin in Advanced Refractory Hodgkin Lymphoma
The Exciting New CML Maze
Rituximab versus Watch and Wait in Follicular Lymphoma... and More
ASH Highlights: Treatment of Multiple Myeloma Continues to Storm Forward
ASH Highlights: MDS 2011 — The Future Ain't What It Used to Be
Issue 8 — March 29, 2011 — Current Edition
Go directly to our slides and commentary on:
Phase I Study of Extended Treatment Schedules of Oral Azacitidine for Patients with MDS, CMML or AML
Azacitidine for Secondary MDS and as a Bridging Option for Patients with MDS/CMML Before Allogeneic Transplant
Single-Agent Lenalidomide as Initial Induction and Postremission Therapy for Older Patients with Del(5q) Acute Myeloid Leukemia (AML)
Lenalidomide and Intensive Chemotherapy for Patients with Higher-Risk MDS or AML with Del(5q)
Novel Strategies Incorporating Arsenic Trioxide into the Initial Treatment of Acute Promyelocytic Leukemia (APL)
Phase I Study of Extended Treatment Schedules of Oral Azacitidine for Patients with MDS, CMML or AML
Azacitidine for Secondary MDS and as a Bridging Option for Patients with MDS/CMML Before Allogeneic Transplant
Single-Agent Lenalidomide as Initial Induction and Postremission Therapy for Older Patients with Del(5q) Acute Myeloid Leukemia (AML)
Lenalidomide and Intensive Chemotherapy for Patients with Higher-Risk MDS or AML with Del(5q)
Novel Strategies Incorporating Arsenic Trioxide into the Initial Treatment of Acute Promyelocytic Leukemia (APL)
ASH Highlights: The Continued Impact of Proteasome Inhibitors and IMiDs in Multiple Myeloma Issue 7 — March 16, 2011
ASH Highlights: Mantle-Cell Blues
Issue 6 — March 7, 2011
Go directly to our slides and commentary on:
High-Dose Ara-C with R-CHOP and Autologous Stem Cell Transplant (ASCT) in Mantle-Cell Lymphoma
Lenalidomide/Dexamethasone as Salvage Treatment in Mantle-Cell Lymphoma (MCL)
R-CHOP-21 Followed by I-131 Tositumomab Consolidation in Diffuse Large B-Cell Lymphoma (DLBCL)
R-CHOP-14 Followed by ICE Consolidation without Radiation Therapy for Primary Mediastinal B-Cell Lymphoma (PMBCL)
High-Dose Ara-C with R-CHOP and Autologous Stem Cell Transplant (ASCT) in Mantle-Cell Lymphoma
Lenalidomide/Dexamethasone as Salvage Treatment in Mantle-Cell Lymphoma (MCL)
R-CHOP-21 Followed by I-131 Tositumomab Consolidation in Diffuse Large B-Cell Lymphoma (DLBCL)
R-CHOP-14 Followed by ICE Consolidation without Radiation Therapy for Primary Mediastinal B-Cell Lymphoma (PMBCL)
An Avalanche of Data in an Uncommon Set of Diseases: 5 ASH Papers on T-Cell Lymphomas Issue 5 — February 22, 2011
Go directly to our slides and commentary on:
Activity and Safety of Pralatrexate and Romidepsin in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Activity and Safety of Brentuximab Vedotin (SGN-35) in Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL)
Activity of Denileukin Diftitox and Pralatrexate in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
Activity and Safety of Pralatrexate and Romidepsin in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Activity and Safety of Brentuximab Vedotin (SGN-35) in Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL)
Activity of Denileukin Diftitox and Pralatrexate in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
ASH Shocker: Brentuximab Vedotin in Advanced Refractory Hodgkin Lymphoma
Issue 4 — February 11, 2011
Go directly to our slides and commentary on:
Brentuximab in Relapsed/Refractory Hodgkin Lymphoma
ABVD versus Stanford V in Hodgkin Lymphoma
PET Scans in Hodgkin Lymphoma
Brentuximab in Relapsed/Refractory Hodgkin Lymphoma
ABVD versus Stanford V in Hodgkin Lymphoma
PET Scans in Hodgkin Lymphoma
The Exciting New CML Maze
Issue 3 — February 2, 2011
Go directly to our slides and commentary on:
Nilotinib in the Early Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Dasatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Systematic Review and Meta-Analysis of the Relative Efficacy of Treatments for Chronic Myeloid Leukemia (CML)
Bosutinib versus Imatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Nilotinib in the Early Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Dasatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Systematic Review and Meta-Analysis of the Relative Efficacy of Treatments for Chronic Myeloid Leukemia (CML)
Bosutinib versus Imatinib in the Initial Management of Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Rituximab versus Watch and Wait in Follicular Lymphoma... and More
Issue 2 — January 21, 2011
Go directly to our slides and commentary on:
Rituximab versus Watch and Wait in the Management of Previously Untreated Asymptomatic Nonbulky Follicular Lymphoma
Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)
Incidence of Therapy-Related Myeloid Neoplasia Among Patients with Chronic Lymphocytic Leukemia (CLL) After Fludarabine/Cyclophosphamide (FC) versus Single-Agent Fludarabine (F) as Initial Treatment
Bortezomib/Rituximab Combination in the Management of Relapsed Follicular Lymphoma
Rituximab versus Watch and Wait in the Management of Previously Untreated Asymptomatic Nonbulky Follicular Lymphoma
Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)
Incidence of Therapy-Related Myeloid Neoplasia Among Patients with Chronic Lymphocytic Leukemia (CLL) After Fludarabine/Cyclophosphamide (FC) versus Single-Agent Fludarabine (F) as Initial Treatment
Bortezomib/Rituximab Combination in the Management of Relapsed Follicular Lymphoma
ASH Highlights: Treatment of Multiple Myeloma Continues to Storm Forward
Issue 1 — January 11, 2011
Go directly to our slides and commentary on:
Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)
Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (MM) or MM in the Post-Transplant Setting
Bortezomib-Based Maintenance Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma (MM)
Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM)
Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)
Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (MM) or MM in the Post-Transplant Setting
Bortezomib-Based Maintenance Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma (MM)
Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM)